Ophthotech (OPHT) Receives Daily Media Impact Rating of 0.04

Media headlines about Ophthotech (NASDAQ:OPHT) have trended somewhat positive on Sunday, according to Accern. Accern identifies positive and negative press coverage by reviewing more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Ophthotech earned a media sentiment score of 0.04 on Accern’s scale. Accern also assigned media headlines about the biopharmaceutical company an impact score of 45.2354596902523 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.

Here are some of the media headlines that may have impacted Accern Sentiment’s rankings:

Ophthotech (NASDAQ:OPHT) opened at $2.94 on Friday. The company has a market cap of $105.95, a price-to-earnings ratio of 1.87 and a beta of 1.58. Ophthotech has a 12-month low of $2.24 and a 12-month high of $4.86.

Ophthotech (NASDAQ:OPHT) last announced its quarterly earnings results on Wednesday, November 8th. The biopharmaceutical company reported $5.25 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $4.38 by $0.87. Ophthotech had a net margin of 26.69% and a negative return on equity of 69.40%. analysts forecast that Ophthotech will post 2.88 earnings per share for the current year.

Several research analysts have commented on OPHT shares. Zacks Investment Research upgraded shares of Ophthotech from a “hold” rating to a “strong-buy” rating and set a $3.25 price target for the company in a report on Monday, November 13th. TheStreet upgraded shares of Ophthotech from an “e+” rating to a “c” rating in a report on Thursday, November 30th. Finally, ValuEngine cut shares of Ophthotech from a “buy” rating to a “hold” rating in a report on Sunday, December 31st.

In other Ophthotech news, insider David R. Guyer sold 16,520 shares of the firm’s stock in a transaction dated Tuesday, January 2nd. The shares were sold at an average price of $3.19, for a total transaction of $52,698.80. Following the sale, the insider now directly owns 50,494 shares of the company’s stock, valued at approximately $161,075.86. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Glenn Sblendorio sold 8,089 shares of the firm’s stock in a transaction dated Tuesday, January 2nd. The stock was sold at an average price of $3.19, for a total transaction of $25,803.91. Following the sale, the chief executive officer now directly owns 44,584 shares in the company, valued at $142,222.96. The disclosure for this sale can be found here. Over the last three months, insiders sold 34,971 shares of company stock worth $111,481. 2.00% of the stock is owned by corporate insiders.

COPYRIGHT VIOLATION NOTICE: “Ophthotech (OPHT) Receives Daily Media Impact Rating of 0.04” was originally published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this report on another website, it was stolen and republished in violation of US and international copyright laws. The legal version of this report can be viewed at https://www.dispatchtribunal.com/2018/01/21/ophthotech-opht-receiving-somewhat-favorable-press-coverage-report-finds.html.

Ophthotech Company Profile

Ophthotech Corporation is a biopharmaceutical company. The Company is engaged in the development of therapeutics to treat ophthalmic diseases, with a focus on diseases of the back of the eye. Its primary focus is developing therapeutics for age-related macular degeneration (AMD), which is a disorder of the central portion of the retina, known as the macula, that may result in blindness.

Insider Buying and Selling by Quarter for Ophthotech (NASDAQ:OPHT)

Receive News & Ratings for Ophthotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ophthotech and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply